编号：2015-001 证券代码：300049 证券简称：福瑞股份 内蒙古福瑞医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |----------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------- ...

编号：2015-002 证券代码：300049 证券简称：福瑞股份 内蒙古福瑞医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Group 1: Company Overview and Operations - The "Love Liver for Life" management centers number approximately 130, establishing partnerships with hospitals to enhance cooperation [2] - The company aims to strengthen deep cooperation with these hospitals this year [2] - The drugstore management project is seen as an upgraded model of the "Love Liver for Life" centers [2] Group 2: Hospital Collaboration and Support - The company assists hospitals in improving discipline construction and introduces advanced medical technologies from larger hospitals [3] - It helps hospitals increase patient retention by providing more services [3] - The targeted hospitals for collaboration are mainly municipal infectious disease hospitals and comprehensive hospitals with strong liver disease departments [3] Group 3: Sales and Marketing Strategy - The existing sales system covers the entire country with a sales team of over 100 people [3] - The company plans to replicate the successful model of Baoding Infectious Disease Hospital as a demonstration for other hospitals [3] - The company is currently relying on other funds to carry out the drugstore management project until the fundraising is completed [3] Group 4: Financial and Market Insights - Baoding Infectious Disease Hospital, a secondary A-level hospital, generates an annual drug revenue of approximately 500,000 to 600,000 yuan [3] - The company has submitted materials for a non-public offering to the China Securities Regulatory Commission, which is currently under review [3] - The company has established a factory in Shenzhen for the domestic production of FibroScan devices, expected to receive registration approval by mid-next year [5] Group 5: Patient Services and Engagement - Patients at the "Love Liver for Life" centers can register, receive follow-up reminders, and communicate with doctors online [4] - The number of doctors managing patients is around 2,000, with over 150,000 patients registered, and a payment rate of approximately 10% [4] - The company offers over 100 types of drugs, covering all clinical medications for liver diseases [5]

Group 1: Financial Performance - The company's overall performance in the first half of the year showed steady growth, with revenue growth outpacing profit growth due to increased R&D expenses and IPO costs [2][3]. - Medical device sales met expectations, with the U.S. market experiencing increased growth and the European market improving, while sales in China remained stable [2][3]. - Pharmaceutical sales showed moderate growth, with both sales prices and raw material costs declining [2][3]. Group 2: Market and Strategic Developments - The company has submitted its IPO application to the Hong Kong Stock Exchange and is currently under review [2][3]. - The U.S. medical device market is large, and previous sales were significantly impacted by insurance issues, which have now been resolved [3]. - The company aims to enhance its service model through deeper collaborations with hospitals, moving beyond simple partnerships [4]. Group 3: Product and Service Innovations - Echosens is focusing on continuous development in liver disease diagnostics, with plans for strategic investments to support U.S. market expansion [3][4]. - The company is upgrading its drug agency model to enhance service delivery, aiming to use profits from pharmaceuticals to drive service upgrades [4]. - The company currently has over 100 types of agency drugs, primarily sourced from manufacturers, to meet hospital demands [4]. Group 4: Insurance and Payment Models - The company plans to integrate both basic medical insurance and commercial insurance into its medical service payment models [4]. - The focus is on collaborating with local commercial companies to enhance service delivery and meet hospital needs [4]. Group 5: Future Outlook - The company anticipates that the successful IPO will provide significant support for its development in terms of funding and technology [2][3]. - There are ongoing discussions about the potential impact of the two-invoice system on sales, but currently, no negative effects have been observed [4].

Group 1: Company Overview and Investment Activities - Inner Mongolia Furu Medical Technology Co., Ltd. is focused on long-term development, with major shareholders expressing confidence despite a low shareholding ratio [2] - The company has terminated its non-public stock issuance project but continues to advance its fundraising projects, now with closer cooperation with hospitals [2] - The company is involved in internet medical services and chronic disease management, aiming to provide more patient services [2] Group 2: Medical Services and Internet Platform - The company is still investing in liver disease management services, which are expected to contribute long-term and flexible benefits [3] - The "Love Liver for Life" internet platform is crucial for accumulating medical resources and is seen as a significant part of the medical service model [3] - The company has increased its investment in the internet medical platform since the second half of last year, with expectations for stable operations depending on healthcare policy reforms [3] Group 3: Financial Performance and Market Strategy - In 2016, the overseas medical project served over 1,000 patients, generating approximately 30 million yuan in revenue [3] - The company aims to provide comprehensive solutions for liver disease patients rather than focusing solely on drug development [4] - The company reported significant growth in sales in the U.S. market, with some growth also in China and Europe [4] Group 4: Research and Development - The company is primarily investing in the development of the FibroScan series and the construction of the internet medical platform [4] - Echosens, a major subsidiary, has seen substantial revenue growth but maintained stable profits due to increased expenses [4] - The company plans to continue using natural cordyceps as a raw material despite the lower cost of artificial alternatives [4] Group 5: Future Outlook and Strategic Partnerships - Echosens is focused on providing comprehensive solutions for liver disease diagnosis, with ongoing projects in collaboration with GE Healthcare [5] - The IPO expenses for Echosens in 2016 were over 3 million euros, with other costs impacting current profits [5] - The major shareholder is considering increasing control over the company when opportunities arise [5]

编号：2017-002 证券代码：300049 证券简称：福瑞股份 内蒙古福瑞医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |---------------------------------------------------------|-----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动类别 | □ | □新闻发布会 □路演活动 \n现场参观 □其他 （请文字说明其他活动内容） | | | | | | 参与单位名称及人员姓 | 国开证券 王雯 | | | 名 | 民生证券 刘淼 中银基金 陈哲 | | | | | | | 时间 | 2017 年 4 月 27 福瑞股份 会议 ...

Company Overview - Founded on November 26, 1998, focusing on liver disease pharmaceuticals, diagnostic equipment, and related medical services [2] - Achieved full licensing in the health industry, covering medical devices, therapeutic drugs, insurance, offline and online medical institutions, and health management [2] - Main product, Compound Turtle Shell Soft Liver Tablets, is the first anti-liver fibrosis drug approved by the National Medical Products Administration, with a market share exceeding 25% [2] Business Segments Pharmaceutical Business - Actively adjusting sales models to enhance product image and explore "drug benefit management" to improve sales resources and bargaining power [3] - The company aims to provide better health management services for liver disease patients while increasing profit margins and risk resistance [3] Diagnostic Equipment - Main product, FibroScan series, is the first non-invasive device using transient elastography technology for liver stiffness measurement, certified by CE, FDA, and CFDA [3] - In 2019, launched two new products, FibroScan HANDY and FibroScan Q, to meet diverse market needs [3] - Plans to collaborate with international pharmaceutical companies to enhance global clinical application of FibroScan [3] Medical Services - Obtained an internet hospital license in early 2020, offering comprehensive online services including consultations, prescriptions, and home delivery [3] - Focus on chronic liver disease management through online follow-ups and health education to improve patient compliance and reduce overall medical costs [3] Market Impact and Strategy - The COVID-19 pandemic has had mixed effects on company performance; plans to increase investor communication and funding for new business initiatives [4] - The French subsidiary's performance showed growth potential despite pandemic-related constraints [4] - The company is developing a fee-for-service model for diagnostic instruments, which is expected to become a significant revenue source in the long term [4] Sales Performance - In 2019, over 50% of diagnostic equipment sales revenue came from the U.S., with Europe contributing about 20% [6] - China accounted for approximately half of the Asian market sales [6] Future Directions - Emphasis on developing products suitable for grassroots medical institutions to meet diverse market demands [6] - Plans to enhance internet hospital operations and support community hospitals in providing quality medical services [7] - Continuous investment in R&D for more intelligent liver disease diagnostic products [6]

Financial Performance - The company's revenue for Q3 2022 reached ¥269,976,553.36, representing a 26.81% increase compared to the same period last year[6]. - Net profit attributable to shareholders for Q3 2022 was ¥28,214,642.45, a significant increase of 76.96% year-over-year[6]. - The net profit after deducting non-recurring gains and losses for Q3 2022 was ¥28,443,206.15, up 91.87% from the previous year[6]. - The company's basic earnings per share for Q3 2022 was ¥0.1073, an increase of 77.94% compared to the same period last year[6]. - Total operating revenue for the current period reached ¥719,049,123.81, an increase of 19.7% compared to ¥600,305,316.55 in the previous period[36]. - Net profit for the current period was ¥95,800,886.56, representing a 16.5% increase from ¥82,242,918.86 in the previous period[38]. - Basic earnings per share increased to ¥0.2310 from ¥0.2250, reflecting a growth of 2.2%[42]. Assets and Liabilities - The total assets as of the end of Q3 2022 were ¥2,437,235,242.09, reflecting a decrease of 3.46% from the end of the previous year[6]. - The company's total liabilities as of September 30, 2022, were CNY 638.11 million, down from CNY 718.97 million at the beginning of the year, indicating a reduction of about 11.2%[31]. - As of September 30, 2022, the company's total assets amounted to approximately CNY 2.44 billion, a decrease from CNY 2.52 billion at the beginning of the year[30]. - The company's cash and cash equivalents decreased to CNY 347.59 million from CNY 472.72 million at the beginning of the year, representing a decline of approximately 26.4%[30]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 18,532[16]. - The largest shareholder, Wang Guan Yi, holds 11.31% of the shares, equating to 29,754,138 shares[16]. - China National Investment High-tech Industry Investment Co., Ltd. holds 6.93% of the shares, totaling 18,240,000 shares[16]. - New Yu Fu Chuang Investment Co., Ltd. owns 6.04% of the shares, amounting to 15,886,000 shares[16]. - The total number of restricted shares at the beginning of the period was 32,398,266, with 44,450 shares released during the period, leaving 32,353,816 restricted shares at the end[22]. - Wang Guan Yi has 22,315,603 restricted shares, which will be released at a rate of 25% annually[19]. Cash Flow and Investments - The cash flow from operating activities for the year-to-date period was ¥109,000,962.13, down 19.18% year-over-year[6]. - The company experienced a 95% decrease in cash received from investment due to reduced minority shareholder contributions[15]. - The company incurred share-based payment expenses of CNY 20.80 million for the first three quarters of 2022 due to the implementation of the employee stock ownership plan[29]. - Cash flow from financing activities resulted in a net cash outflow of -207,658,400.75, compared to -7,009,504.51 in the previous period, indicating increased financial strain[44]. - Cash paid for dividends and interest was 160,809,712.11, significantly higher than 21,210,043.42 in the previous period, indicating increased shareholder returns[44]. Research and Development - Research and development expenses increased by 31% to ¥52,028,613.67 due to higher investment by the French subsidiary[12]. - Research and development expenses rose to ¥52,028,613.67, up 31.2% from ¥39,652,726.97 in the prior period[36]. Project Development - The company is continuing the construction of the Furu Health Technology Park project, with support from the local government[23]. - The project was previously at risk due to land use rights recovery but has now been supported for continuation[24].

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 449,072,570.45, representing a 15.92% increase compared to CNY 387,402,455.57 in the same period last year[24]. - The net profit attributable to shareholders of the listed company decreased by 22.93% to CNY 32,547,964.21 from CNY 42,229,381.30 year-on-year[24]. - Basic earnings per share decreased by 24.89% to CNY 0.1237 from CNY 0.1647 in the same period last year[24]. - The company reported a decrease in diluted earnings per share by 22.93% to CNY 0.1237 from CNY 0.1605 year-on-year[24]. - The net cash flow from operating activities fell by 53.52% to CNY 41,864,609.74, down from CNY 90,071,009.01 in the previous year[24]. - The company reported a total investment of 61.29 million yuan for the production base technology transformation project, with an actual investment of 31.86 million yuan, resulting in a surplus of 29.43 million yuan[86]. - The company reported a net profit margin improvement, with undistributed profits rising to CNY 206,767,378.45 from CNY 200,516,745.23, an increase of about 3.6%[185]. - The company's net profit for the first half of 2022 was CNY 53,252,868.49, a decrease of 11.2% compared to CNY 59,929,745.44 in the same period of 2021[188]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,430,978,502.35, a decrease of 3.71% from CNY 2,524,643,000.05 at the end of the previous year[24]. - The net assets attributable to shareholders of the listed company decreased by 0.43% to CNY 1,513,095,593.00 from CNY 1,519,561,332.55 at the end of the previous year[24]. - Cash and cash equivalents at the end of the reporting period amounted to ¥396,743,062.66, representing 16.32% of total assets, a decrease of 2.40% from the previous year[57]. - Accounts receivable increased to ¥361,397,078.38, accounting for 14.87% of total assets, up by 1.56% year-on-year[57]. - Inventory reached ¥102,536,218.44, which is 4.22% of total assets, reflecting a slight increase of 0.24% compared to the previous year[57]. - Total liabilities decreased to CNY 355,546,359.19 from CNY 400,326,828.28, reflecting a reduction of approximately 11.2%[185]. Revenue Segments - The pharmaceutical business generated revenue of 158.05 million yuan, up 11.26% year-on-year, with e-commerce channel revenue increasing by 38.83%[32]. - The medical device segment reported revenue of 38.32 million euros, a year-on-year increase of 27.65%, and net profit of 6.05 million euros, up 37.27%[36]. - The pediatric healthcare management business saw a revenue increase of 150.37% year-on-year, with three new direct-operated clinics opened in Chengdu[37]. - The revenue from medical services increased by 100.23% to ¥18,249,642.48, reflecting strong growth in this segment[51]. - The company’s international sales accounted for ¥256,042,707.11, showing a growth of 19.95% year-on-year, while domestic sales increased by 10.97%[51]. Research and Development - The company’s R&D investment rose by 6.40% to ¥48,987,756.62, indicating a continued focus on product development and innovation[51]. - The company plans to focus R&D resources on advanced diagnostic technology in the French business sector due to significant changes in the internal and industry environment[76]. Strategic Initiatives - The company is focusing on the "Love Liver for Life" project to enhance liver disease management and improve treatment rates through a collaborative model with hospitals[38]. - The company plans to promote FibroScan as a key standard in the global NASH detection field, enhancing clinical application demand[36]. - The company is committed to a full-cycle management approach in the liver disease sector, integrating diagnostics, treatment, and patient management[47]. Shareholder Information - The company held its annual shareholders' meeting on May 30, 2022, with a participation rate of 25.07%[100]. - The employee stock ownership plan includes 65 participants, holding a total of 6,718,233 shares, representing 2.55% of the company's total equity[101]. - The largest shareholder, Wang Guan Yi, holds 11.31% of the shares, totaling 29,754,138 shares[155]. - The company has a total of 32,398,266 restricted shares, accounting for 12.32% of total shares after the change[148]. Compliance and Governance - The company did not face any administrative penalties related to environmental issues during the reporting period, indicating compliance with environmental regulations[110]. - The company confirmed that it is not classified as a key pollutant discharge unit by environmental authorities, ensuring its operations are environmentally compliant[110]. - The company has committed to avoiding any activities that may lead to competition with its controlling shareholder, ensuring stable governance[115]. Risks and Challenges - The company faces risks from macroeconomic changes and external environments, including the ongoing pandemic and geopolitical tensions, and plans to enhance its core competitiveness[89]. - The procurement price of key raw materials, particularly Cordyceps sinensis, is subject to market supply and demand fluctuations, which may impact the company's gross profit margin[92]. - The medical service business currently contributes relatively low revenue and profit, with a risk of underperformance in future development due to long cultivation periods and significant policy influence[92].

Financial Performance - The company's operating revenue for 2020 was ¥807,532,608.20, representing an increase of 11.26% compared to 2019[22]. - The net profit attributable to shareholders for 2020 was ¥61,905,640.52, reflecting a growth of 54.22% year-over-year[22]. - The net profit after deducting non-recurring gains and losses was ¥68,157,758.84, up 34.62% from the previous year[22]. - The total assets at the end of 2020 amounted to ¥2,290,529,206.59, which is a 10.22% increase from the end of 2019[22]. - The net assets attributable to shareholders reached ¥1,352,027,929.99, marking a 12.39% increase compared to the previous year[22]. - The basic earnings per share for 2020 was ¥0.2415, an increase of 52.22% from ¥0.1693 in 2019[22]. - The cash flow from operating activities for 2020 was ¥200,151,631.24, showing a slight increase of 4.08% from the previous year[22]. - The total revenue for the year 2021 was approximately ¥898.48 million, representing an increase of 11.26% compared to ¥807.53 million in 2020[61]. - The company achieved operating revenue of ¥332,644,187.55 in 2021, representing a growth of 4.20% compared to the previous year[41]. - The revenue from medical devices and technology accounted for 60.75% of total revenue, amounting to ¥545.81 million, with a year-on-year growth of 14.26%[61]. - The company reported a total revenue of ¥298,177,912.14 in Q4 2021, with a net profit of ¥37,295,143.30 for the same quarter[26]. Investment and Assets - The company holds a 50.13% stake in Echosens, which generated a net profit of ¥108,139,932.58 during the reporting period, contributing to 18.94% of the company's net assets[94]. - The total investment during the reporting period was ¥30,478,301.20, a decrease of 69% compared to the previous year[103]. - The company has a remaining balance of 1,328.95 million CNY in the fundraising special account[110]. - The total fair value of financial assets at the end of the period is 431,643.802 million CNY, with a cumulative investment income of 6,836,214 CNY[107]. - The company has not identified any significant impairment risks for its overseas assets, which account for 11.20% of the company's net assets[94]. - The company has a total of ¥70,559,354.36 in restricted assets due to mortgage loans[99]. - The construction in progress decreased to ¥182,145,653.25, reflecting a decline of 3.09%[94]. Research and Development - Research and development expenses for 2021 were ¥64,792,211.85, a decrease of 1.57% compared to 2020[75]. - The total R&D investment for 2021 was ¥98,668,071.46, representing 10.98% of operating revenue[79]. - The number of R&D personnel decreased by 6.10% from 82 in 2020 to 77 in 2021[79]. - The company is currently developing an upgraded version of Fibroscan to expand its product offerings and enhance global market competitiveness[76]. - The company has completed the data modeling and patent application for the FSTM project, achieving satisfactory research results[114]. Governance and Compliance - The company emphasizes that all board members attended the meeting to review the annual report, ensuring accountability for the report's accuracy and completeness[3]. - The company has maintained a governance structure that aligns with the requirements set by the China Securities Regulatory Commission, ensuring transparency and accountability[155]. - The company has a total of 11 board members, including 4 independent directors, complying with legal and regulatory requirements[153]. - The company has a financial independence system with an independent finance department and bank accounts, ensuring no interference from major shareholders in financial decisions[162]. - The company has established various committees within the board, including a strategic development committee and an audit committee, to enhance decision-making processes[153]. - The company has ensured that all shareholders have equal rights and access to information, maintaining fairness in shareholder meetings[152]. Market Strategy and Expansion - The company is focusing on the development of chronic disease treatment opportunities, following new regulations on long-term prescriptions issued by the National Health Commission[36]. - The company is actively developing new products and expanding the application scenarios of FibroScan in the medical field[45]. - The company is focusing on enhancing brand recognition and market share for its flagship product, the Compound Turtle Shell Soft Liver Tablet[43]. - The company aims to expand its market presence in liver disease and pediatric sectors while transitioning to managed healthcare[128]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% market share by 2025[184]. Risk Management - The company aims to enhance risk prevention by establishing a comprehensive risk control system, focusing on key areas such as drug quality management and procurement[133]. - The company faces risks from macroeconomic changes, with strategies in place to adapt to the new development pattern of domestic and international dual circulation[138]. - The company is managing the risk of raw material price fluctuations, particularly for winter worm grass, which significantly impacts production costs[142]. - The company is aware of the potential underperformance of new business developments in medical services and is actively optimizing its business models[143]. Human Resources and Remuneration - The total remuneration paid to directors, supervisors, and senior management in 2021 amounted to 6.7425 million yuan[200]. - The remuneration for directors and supervisors is determined based on performance, capability, and position level, and is approved by the board and supervisory committee[200]. - The company has established a performance evaluation scheme for senior management approved by the chairman[200]. - The company has increased its workforce by incorporating new talent and focusing on training and performance assessment[57]. Social Responsibility and Community Engagement - The company is committed to supporting social medical enterprises and improving the policy environment for their development[40]. - The company is focusing on integrating global resources to support the "Healthy China" strategy, providing comprehensive and convenient medical services[128].